News

Throughout 2019, Pulmonary Fibrosis News provided you daily coverage of breakthrough discoveries, promising therapies, and clinical trials related to pulmonary fibrosis (PF). As we look forward to bringing more news to patients, family members, and caregivers dealing with PF in 2020, here are the top 10 most-read articles of 2019,…

Overactivation of a protein called mucin 1 (MUC1) triggers pro-fibrotic transformations in the lungs that could contribute to the development and progression of idiopathic pulmonary fibrosis (IPF), an early study using patient cells and mice has found. The research furthers knowledge about the roles played by MUC1-induced pathways,…

Cohbar’s new investigational mitochondrial peptide (a small protein) called MBT#2, not only prevented scarring (fibrosis), but also slowed disease progression when fibrosis was already established in a mouse model of idiopathic pulmonary fibrosis (IPF), according to preclinical data. The new data was shared on the company’s website…

miRagen Therapeutics is reshaping its strategy to focus on the development of MRG-229, a potential treatment for idiopathic pulmonary fibrosis (IPF). The company expects to share new efficacy and safety preclinical data on MRG-229 during the…

People with pulmonary fibrosis living in the Mercer and Bucks County regions of New Jersey and Pennsylvania now have access to a new pulmonary rehabilitation program. The program, launched by Capital Health in December, will be located at the Wellness Center at Capital Health Medical Center –…

A novel lab model replicates the main steps leading to progressive fibrosis, and can be used to assess the properties of therapeutic candidates, a study has found. The study, “Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule,” was published in the journal…

Men with idiopathic pulmonary fibrosis (IPF) have poorer lung function and a higher frequency of heart-related diseases (comorbidities) than women with IPF, according to a Swedish study. The data, which showed no differences between the sexes in terms of quality of life, suggest that additional research is required to…

The Canadian Registry for Pulmonary Fibrosis (CARE-PF) enrolled in its first 18 months more than 1,200 people with interstitial lung disease (ILD), with more than half having either idiopathic pulmonary fibrosis (IPF) or connective tissue disease-associated interstitial lung disease (CTD-ILD). Data collected through the CARE-PF registry could be useful…

Algernon Pharmaceuticals‘s NP-120 (ifenprodil) outperformed Merck‘s MK-7264 (gefapixant) in an animal model of acute cough, a preclinical study by a contract research organization (CRO) shows. NP-120 is Algernon’s repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), while MK-7264 is Merck’s lead candidate for the treatment…

Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis (IPF), will start in the coming weeks, Genkyotex announced in a progress report. Following approval by the U.S. Food and Drug Administration (FDA) in July, the study protocol now…